- Home
- MRNS
as 05-17-2024 4:00pm EST
Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19-RE.
| Founded: | 2003 | Country: | United States |
| Employees: | N/A | City: | RADNOR |
| Market Cap: | 73.1M | IPO Year: | 2014 |
| Target Price: | $11.75 | AVG Volume (30 days): | 2.0M |
| Analyst Decision: | Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.64 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.11 - $11.26 | Next Earning Date: | 05-08-2024 |
| Revenue: | $28,288,000 | Revenue Growth: | 30.53% |
| Revenue Growth (this year): | 33.41% | Revenue Growth (next year): | 64.37% |
Share on Social Networks:
Stock Insider Trading Activity of Marinus Pharmaceuticals Inc. (MRNS)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| MANNING MARTHA E | MRNS | SVP, GEN. COUNSEL & CORP. SEC. | Feb 20 '24 | Sell | $9.57 | 1,894 | $18,125.58 | 52,966 | SEC Form 4 |
| Pfanstiel Steven | MRNS | CFO AND COO | Feb 16 '24 | Sell | $9.97 | 3,092 | $30,827.24 | 71,697 | SEC Form 4 |
| Hulihan Joseph | MRNS | CHIEF MEDICAL OFFICER | Feb 16 '24 | Sell | $9.98 | 2,814 | $28,083.72 | 66,635 | SEC Form 4 |
| Braunstein Scott | MRNS | CHAIRMAN AND CEO | Feb 16 '24 | Sell | $9.94 | 11,850 | $117,789.00 | 223,512 | SEC Form 4 |
Latest Marinus Pharmaceuticals Inc. News
MRNS Breaking Stock News: Dive into MRNS Ticker-Specific Updates for Smart Investing
MT Newswires
2 days ago
Marinus Completes Enrollment in Tuberous Sclerosis Complex Trial; Gets New Patent
Zacks
2 days ago
Here's Why Marinus Pharmaceuticals (MRNS) is Poised for a Turnaround After Losing -7.8% in 4 Weeks
Business Wire
3 days ago
Marinus Pharmaceuticals Announces Key Business Updates for Tuberous Sclerosis Complex Program
Zacks
3 days ago
After Plunging -7.64% in 4 Weeks, Here's Why the Trend Might Reverse for Marinus Pharmaceuticals (MRNS)
Simply Wall St.
8 days ago
Earnings Release: Here's Why Analysts Cut Their Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Price Target To US$8.00
Zacks
11 days ago
Marinus Pharmaceuticals (MRNS) Reports Q1 Loss, Lags Revenue Estimates
Associated Press Finance
11 days ago
Marinus Pharmaceuticals: Q1 Earnings Snapshot
Business Wire
12 days ago